Long-term Follow-up and Safety of Patients after an Upfront Therapy with Letrozole for Early Breast Cancer in Routine Clinical Care - The PreFace Study.
Carolin C HackNicolai MaassBahriye AktasSherko KümmelChristoph ThomssenChristopher WolfHans-Christian KolbergCosima BruckerWolfgang JanniPeter DallAndreas SchneeweissFrederik MarmeMatthias RuebnerAnna-Katharin TheuserNadine M HofmannSybille BöhmKatrin AlmstedtSara KellnerPaul GassMarc W SütterlinHans-Joachim LückSabine SchmatlochMatthias KalderChristoph UleerIngolf Juhasz-BössVolker HanfChristian JackischVolkmar MüllerBrigitte RackErik BellevilleDiethelm WallwienerAchim RodyClaudia RauhChristian M BayerSabrina UhrigChloë GoossensHanna HuebnerSara Y BruckerLothar HäberleTanja N FehmAlexander HeinPeter A FaschingPublished in: Geburtshilfe und Frauenheilkunde (2024)
The risk profile of postmenopausal BC patients selected for a five-year upfront letrozole therapy showed a moderate recurrence and death risk. However, in subgroups with unfavorable risk factors, prognosis warrants an improvement, which might be achieved with novel targeted therapies.
Keyphrases
- end stage renal disease
- early breast cancer
- ejection fraction
- risk factors
- newly diagnosed
- chronic kidney disease
- prognostic factors
- peritoneal dialysis
- type diabetes
- palliative care
- stem cells
- patient reported outcomes
- clinical practice
- polycystic ovary syndrome
- mesenchymal stem cells
- body composition
- quality improvement
- chronic pain
- bone mineral density